Logotipo del repositorio
Logotipo del repositorio
 

Second Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))

Vista sencilla de ítem
dc.contributor.authorRoldan Menco, Consuelo
dc.contributor.authorDíaz-Pérez, Anderson
dc.contributor.authorBarrios Puerta, Zoraida
dc.date.accessioned2019-05-15T20:00:01Z
dc.date.available2019-05-15T20:00:01Z
dc.date.issued2019
dc.description.abstractIntroduction: The Metabolic Syndrome is a set of diverse clinical situations such as diabetes mellitus, hypertension and dyslipidemia. Patients with mental illnesses such as schizophrenia or bipolar disorder have a higher mortality than the general population attributable in 60% to somatic diseases and metabolic syndrome, where second generation antipsychotics increase the risk of weight gain and insulin resistance. Objectives. Correlate the treatment with second generation antipsychotics (SGAs) as a possible predictor for Metabolic Syndrome according to the NCEP ATP III (a) classification. Methods: Descriptive, cross-sectional correlational study. The sample was of 92 patients, applying an open and convenience sampling due to the mental state of the patients in order to determine their degree of acceptance to the study (Informed Assent) and consent to the legal guardian as the main inclusion criterion. For the analysis, the following variables were considered: blood pressure, weight, height, abdominal circumference, serum levels of triglycerides, glucose and high density lipoproteins. The SPSS 20.0 ® program was used logistic regression analysis with a p-value <0.05 and a confidence level of 95%. Results: SGAs most used was clozapine (54.3%). The correlation analysis showed that sociodemographic aspects such as personal history, habits, physical activity and paraclinical and anthropometric records correlated with the possible diagnosis of metabolic syndrome (p <0.05), but not with SGAs (p> 0.05). ). Conclusion: No correlation was found between the presence of the metabolic syndrome and the type of antipsychotic treatment.eng
dc.identifier.issn19169736
dc.identifier.urihttp://hdl.handle.net/20.500.12442/3021
dc.language.isoengeng
dc.publisherCanadian Center of Science and Educationeng
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.accessrightsinfo:eu-repo/semantics/openAccesseng
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceGlobal Journal of Health Scienciaeng
dc.sourceVol. 11, No. 1 (2019)eng
dc.source.urihttps://doi.org/10.5539/gjhs.v11n1p28eng
dc.subjectSecond generation antipsychoticseng
dc.subjectSchizophrenic patientseng
dc.subjectBipolar disordereng
dc.subjectMetabolic syndromeeng
dc.titleSecond Generation Antipsychotics (SGAs) in Schizophrenic Patients and Bipolar Disorder: Correlation With Metabolic Syndrome (NCEP ATP III(a))eng
dc.typearticleeng
dcterms.referencesAguilar, E., Coronas, R., & Caixàs, A. (2012). Síndrome metabólico en pacientes esquizofrénicos con tratamiento antipsicótico. Medicina clínica, 139(12), 542-546. https://doi.org/10.1016/j.medcli.2012.05.028spa
dcterms.referencesAlberti, K. G. M. M., Zimmet, P., & Shaw, J. (2006). Metabolic syndrome—a new world-wide definition. A consensus statement from the international diabetes federation. Diabetic medicine, 23(5), 469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.xeng
dcterms.referencesAtun, R., De Andrade, L. O. M., Almeida, G., Cotlear, D., Dmytraczenko, T., Frenz, P., … Muntaner, C. (2015). Health-system reform and universal health coverage in Latin America. The Lancet, 385(9974), 1230-1247. https://doi.org/10.1016/S0140-6736(14)61646-9eng
dcterms.referencesChoo CC, Chew PKH, Ho CS, Ho RC. Prediction of Quality of Life in Asian Patients with Schizophrenia: A Cross-sectional Pilot Study. Front Psychiatry, 5(8), 198. https://doi.org/10.3389/fpsyt.2017.00198eng
dcterms.referencesCorrell, C. U., Detraux, J., Lepeleire, J., & De Hert, M. (2015). Efectos de antipsicóticos, antidepresivos y estabilizadores del estado de ánimo sobre el riesgo de enfermedades físicas en personas con esquizofrenia, depresión y trastorno bipolar. WPA, 14, 119-136.spa
dcterms.referencesCortés Morales, B. (2011). Síndrome metabólico y antipsicóticos de segunda generación. Revista de la Asociación Espa-ola de Neuropsiquiatría, 31(2), 303-320. https://doi.org/10.4321/S0211-57352011000200009spa
dcterms.referencesDe Hert, M., Dekker, J. M., Wood, D., Kahl, K. G., & Möller, H.-J. (2009). Enfermedad cardiovascular y diabetes en personas con enfermedad mental grave: Declaración de la posición de la Sociedad Psiquiátrica Europea (EPA), respaldada por la Asociación Europea para el Estudio de la Diabetes (EASD) y la Sociedad Europea de Cardiología (ESC). Revista de Psiquiatría y Salud Mental, 2(1), 49-59. https://doi.org/10.1016/S1888-9891(09)70714-1spa
dcterms.referencesEstévez, M. J. V., Domínguez, M. F., Corti-as, M. J. L., Seoane, M. N., Sánchez, E. P., & Quintas, C. M. G. (2013). Prevalencia del síndrome metabólico en esquizofrenia y trastorno bipolar:?` sería útil un protocolo de control cardiovascular? Cadernos de atención primaria, 19(4), 215–222.spa
dcterms.referencesExpert Panel on Detection, E. (2001). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Jama, 285(19), 2486. https://doi.org/10.1001/jama.285.19.2486eng
dcterms.referencesFirmann, M., Mayor, V., Vidal, P. M., Bochud, M., Pécoud, A., Hayoz, D., … Yuan, X. (2008). The CoLaus study: a population-based study to investigate the epidemiology and genetic determinants of cardiovascular risk factors and metabolic syndrome. BMC cardiovascular disorders, 8(1), 6. https://doi.org/10.1186/1471-2261-8-6eng
dcterms.referencesGarcía-García, E., la Llata-Romero, D., Kaufer-Horwitz, M., Tusié-Luna, M. T., Calzada-León, R., Vázquez-Velázquez, V., … Velázquez-Fernández, D. (2008). La obesidad y el síndrome metabólico como problema de salud pública. Una reflexión. Acta pediátrica de México, 29(4), 227-245.spa
dcterms.referencesGrundy, S. M., Cleeman, J. I., Merz, C. N. B., Brewer, H. B., Clark, L. T., Hunninghake, D. B., … Program, C. C. of the N. C. E. (2004). Implications of recent clinical trials for the national cholesterol education program adult treatment panel III guidelines. Journal of the American College of Cardiology, 44(3), 720-732. https://doi.org/10.1016/j.jacc.2004.07.001eng
dcterms.referencesHeng, D., Ma, S., Lee, J. J., Tai, B. C., Mak, K. H., Hughes, K., … Tai, E. S. (2006). Modification of the NCEP ATP III definitions of the metabolic syndrome for use in Asians identifies individuals at risk of ischemic heart disease. Atherosclerosis, 186(2), 367-373. https://doi.org/10.1016/j.atherosclerosis.2005.07.020eng
dcterms.referencesHo, C. S., Zhang, M. W., Mak, A., Ho, R. C. (2014). Metabolic syndrome in psychiatry: advances in understanding and management. Advances in Psychiatric Treatment, 20, 101-112. https://doi.org/10.1192/apt.bp.113.011619eng
dcterms.referencesJaramillo, C. L., Mejía, A. C., Velásquez, A. H., Palacio, T. F. R., & Zuluaga, J. O. (2013). Síndrome metabólico y trastorno afectivo bipolar: una revisión de la literatura. Revista Colombiana de Psiquiatría, 42(3), 283-291. https://doi.org/10.1016/S0034-7450(13)70021-0spa
dcterms.referencesKavey, R.-E. W., Daniels, S. R., Lauer, R. M., Atkins, D. L., Hayman, L. L., & Taubert, K. (2003). American Heart Association guidelines for primary prevention of atherosclerotic cardiovascular disease beginning in childhood. Circulation, 107(11), 1562–1566. https://doi.org/10.1161/01.CIR.0000061521.15730.6Eeng
dcterms.referencesLakka, H.-M., Laaksonen, D. E., Lakka, T. A., Niskanen, L. K., Kumpusalo, E., Tuomilehto, J., & Salonen, J. T. (2002). The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama, 288(21), 2709-2716. https://doi.org/10.1001/jama.288.21.2709eng
dcterms.referencesLevav, I., Lima, B. R., Somoza Lennon, M., Kramer, M., & Salvatierra-González, R. (1989). Salud mental para todos en America Latina y el Caribe: bases epidemiologicas para la accion.spa
dcterms.referencesMartinez, M. I. V., León, F., Torres, R., & Crossley, N. A. (2017). Antipsicóticos de primera y segunda generación en esquizofrenia: eficacia, efectividad y efecto de la dosis utilizada. ARS MEDICA Revista de Ciencias Médicas, 42(1), 41-48. https://doi.org/10.11565/arsmed.v42i1.452spa
dcterms.referencesMcEvoy, J. P., Meyer, J. M., Goff, D. C., Nasrallah, H. A., Davis, S. M., Sullivan, L., … Lieberman, J. A. (2005). Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophrenia research, 80(1), 19-32. https://doi.org/10.1016/j.schres.2005.07.014eng
dcterms.referencesMenco, C. R., & Pérez, A. D. (2011). Otros factores asociados con síndrome metabólico? Ciencia y Salud Virtual, 3(1), 135-143. https://doi.org/10.22519/21455333.300spa
dcterms.referencesMoreno, T. S.-A., González, R. T., Fleta, J. L. H., & Pérez, P. L. (2006). Alta prevalencia de síndrome metabólico en pacientes esquizofrénicos: una revisión de la literatura. Psiquiatría Biológica, 13(4), 127–135. https://doi.org/10.1016/S1134-5934(06)75353-2spa
dcterms.referencesMu-oz, P., & Gallardo, R. (2004). Trastornos metabólicos en pacientes esquizofrénicos tratados con Clozapina.spa
dcterms.referencesMu-oz-Calero Franco, P., Sánchez Sánchez, B., Rodríguez Criado, N., Pinilla Santos, B., Bravo Herrero, S., Fourcade, C., … Martín Aragón, R. (2015). Síndrome metabólico y riesgo cardiovascular en pacientes con diagnóstico de esquizofrenia, trastorno esquizoafectivo y trastorno bipolar. Nutrición Hospitalaria, 32(6), 2715–2717.spa
dcterms.referencesNewcomer, J. W. (2007a). Antipsychotic medications: metabolic and cardiovascular risk. The Journal of clinical psychiatry.eng
dcterms.referencesNewcomer, J. W. (2007b). Metabolic syndrome and mental illness. The American journal of managed care, 13(7 Suppl), S170-7.eng
dcterms.referencesOrtiz Lobo, A., & Ibá-ez Rojo, V. (2011). Iatrogenia y prevención cuaternaria en salud mental. Revista Espa-ola de Salud Pública, 85(6), 513-525. https://doi.org/10.1590/S1135-57272011000600002spa
dcterms.referencesPark, B., & Lee, Y.-J. (2018). Metabolic syndrome and its components as risk factors for prolonged corrected QT interval in apparently healthy Korean men and women. Journal of Clinical Lipidology. https://doi.org/10.1016/j.jacl.2018.07.004eng
dcterms.referencesPato, C. M. F., Rodríguez, V. M., & Valverde, J. I. F. (2017). Síndrome metabólico y antipsicóticos atípicos. Posibilidad de predicción y control. Revista de Psiquiatría y Salud Mental, 10(1), 38-44. https://doi.org/10.1016/j.rpsm.2016.09.003spa
dcterms.referencesPineda, C. A. (2008). Síndrome metabólico: definición, historia, criterios. Colombia médica, 39(1).spa
dcterms.referencesRojo, L., Mesa, F., & Martínez-Ortega, J. M. (2014). Prevalencia del síndrome metabólico en pacientes espa-oles con esquizofrenia y sobrepeso. El estudio CRESSOB. Actas Esp Psiquiatr, 42(1), 9-17.spa
dcterms.referencesStergiou, G. S., Asmar, R., Myers, M., Palatini, P., Parati, G., Shennan, A., … Monitoring, E. S. of H. W. G. on B. P. (2018). Improving the accuracy of blood pressure measurement: the influence of the European Society of Hypertension International Protocol (ESH-IP) for the validation of blood pressure measuring devices and future perspectives. LWW. https://doi.org/10.1097/HJH.0000000000001635eng
dcterms.referencesThomas, G. N., Ho, S.-Y., Janus, E. D., Lam, K. S., Hedley, A. J., Lam, T. H., & Committee, H. K. C. R. F. P. S. S. (2005). The US national cholesterol education programme adult treatment panel III (NCEP ATP III) prevalence of the metabolic syndrome in a Chinese population. Diabetes research and clinical practice, 67(3), 251-257. https://doi.org/10.1016/j.diabres.2004.07.022eng
dcterms.referencesVancampfort, D., Stubbs, B., Mitchell, A. J., De Hert, M., Wampers, M., Ward, P. B., … Correll, C. U. (2015). Risk of metabolic syndrome and its components in people with schizophrenia and related psychotic disorders, bipolar disorder and major depressive disorder: a systematic review and meta-analysis. World Psychiatry, 14(3), 339-347. https://doi.org/10.1002/wps.20252eng
dcterms.referencesWilliams, B., Poulter, N. R., Brown, M. J., Davis, M., McInnes, G. T., Potter, J. F., … Thom, S. M. (2004). Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. Journal of human hypertension, 18(3), 139. https://doi.org/10.1038/sj.jhh.1001683eng

Archivos

Bloque original
Mostrando 1 - 1 de 1
Miniatura
Nombre:
Second Generation Antipsychotics (SGAs) in Schizophrenic Patients .pdf
Tamaño:
196.03 KB
Formato:
Adobe Portable Document Format
Descripción:
PDF
Descargar
Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
368 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca